- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03049397
Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer
Family Functioning and Bereavement Outcomes Following the Enhancing Connections Program in Palliative Care
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVES:
I. Test the feasibility of the study protocol in advanced cancer patients and co-parents (recruitment/retention, dosage and fidelity of the intervention; program acceptability of program; and logistics).
II. Evaluate the short-term impact of the program on the diagnosed parents', co-parents' and children's adjustment and family functioning using a within group design (pre- and posttest design).
III. Compare outcomes from the Enhancing Connections Palliative Program with similar outcomes obtained from the completed phase III trial (between group design) for the patients and children outcomes.
IV. Evaluate the longer term impact of the program on the co-parents' and children's adjustment, including bereavement outcomes when appropriate, using a within and across group design (pre- and posttest design).
OUTLINE:
Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone. Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
After completion of the study, participants are followed-up at 6 months.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
PATIENTS
- Ages 25-65 years
- Have a diagnosis of incurable cancer of any type; at any time in the diagnosis as long as they have at least a 4 month life expectancy based on the opinion of the attending physician
- Read and write English among their languages of choice
- Parent must live at least 50% of the time in the home and have a child 5-17 years old living at home who has been told their parent's cancer diagnosis
CO-PARENTS
- Co-parents must reside with the consenting eligible cancer participant (and child) at least 50% of the time and be actively participating in the care of the child
- If a biological parent lives in the home, and is physically well themselves, this person must be the co-parent
- If a biological parent does not live in the home (or has died), the co-parent does not have to be a biological parent; therefore, co-parents may be step-parents, lesbian, gay, bi-sexual or transgender (LGBT) partners, grandparents, aunts, uncles, etc if they otherwise meet eligibility criteria
- He or she can read and write English among their languages of choice and agrees to attend the patient intervention sessions in person or by telephone
CHILDREN
- The patient and co-parent must agree to focus on the same child throughout the study and consent to have the child participate before the child's assent will be sought
- Children aged 5-13 years of age will participate with a waiver of assent
- Children aged 14-17 will assent to participate in the research study by signing a separate assent form
- Children of formal assenting age will be eligible to participate if they can read and write English among their languages of choice
ALL PARTICIPANTS
- Participants must live within 35 miles of the University of Washington, Seattle, WA to receive the in-person version of the intervention
- Parents and co-parents selecting the telephone version of the intervention may live any distance from the University of Washington
Exclusion Criteria:
- Patients will be excluded if they are enrolled in hospice at time of enrollment; however, they will be allowed to continue in the study if they enroll in hospice after beginning the study
- The triad will be ineligible if any member lives in the home less than 50% of the time
- If any member of the triad retracts consent or assent prior to completion of the post-intervention surveys, then all members will be excluded from the study thereafter
- The child will be excluded if he or she has learning challenges as assessed by the patient or co-parent; patients and co-parents will be instructed to consider any formal diagnoses of a learning disability of the presence of an Individual Education Plan (IEP) when making this assessment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Supportive Care (Enhancing Connections program)
Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone.
Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
|
Estudos auxiliares
Complete Enhancing Connections program
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Feasibility of the Enhancing Connections program in advanced cancer patients and co-parents
Prazo: Up to 2 years
|
Recruitment and retention of all triads will be monitored.
Dosage and fidelity will be monitored for each intervention session.
Program acceptability (per session, overall, duration of program, interval between intervention sessions) will be assessed from a debriefing interview.
For logistics four areas will be monitored: rate of receipt of mailed materials both to participants and from participants; duration and type (whether telephone or in-person) of intervention sessions; rate of success in scheduling and completing intervention sessions with patient and co-parent; and quality of data on baseline, post-intervention and follow-up measures.
|
Up to 2 years
|
|
Change in adjustment and family functioning
Prazo: Baseline to 6 months
|
Descriptive statistics (e.g.
means, medians) will be used to describe the Enhancing Connections palliative care population.
Parents', co-parents and children's baseline scores [parent-reported] on standardized questionnaires will be compared with post-intervention and 6 month follow-up scores on the same measures.
|
Baseline to 6 months
|
|
Outcomes from the Enhancing Connections Palliative Program as measured by the Child Behavior Check List
Prazo: Up to 2 years
|
Linear mixed modeling based on Maximum Likelihood Estimation will be used to test the differences between the Child Behavior Check List results for the Enhancing Connections Palliative Program and the completed phase III trial (EC-R01).
|
Up to 2 years
|
|
Change in adjustment as measured by post-traumatic growth scores
Prazo: Baseline to 6 months
|
Enhancing Connection Palliative Program parents', co-parents' and children's post-traumatic growth scores will be compared with follow-up (6 month) scores on the same measure.
|
Baseline to 6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Elizabeth Loggers, Fred Hutch/University of Washington Cancer Consortium
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 9667 (Outro identificador: Fred Hutch/University of Washington Cancer Consortium)
- P30CA015704 (Concessão/Contrato do NIH dos EUA)
- NCI-2016-01640 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- RG9218011 (Outro identificador: Fred Hutch/University of Washington Cancer Consortium)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Neoplasia Maligna Avançada
-
Advanced BionicsConcluídoPerda auditiva severa a profunda | em usuários adultos do Advanced Bionics HiResolution™ Bionic Ear SystemEstados Unidos
-
Tianjin Medical University Cancer Institute and...RecrutamentoAvaliando a eficácia da terapia combinada do TROP-2 ADC em câncer de mama Advanced Triple-NegativeChina
Ensaios clínicos em Administração do Questionário
-
Radboud University Medical CenterHoffmann-La RocheRecrutamentoNefropatia Membranosa - Induzida por PLA2RHolanda
-
Peking University Third HospitalAinda não está recrutandoOsteoporose | Distúrbios do Ritmo Circadiano